Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eftozanermin alfa + bortezomib + dexamethasone
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
**Eftozanermin alfa + bortezomib + dexamethasone** is an investigational combination therapy being studied for the treatment of relapsed or refractory multiple myeloma. *Eftozanermin alfa* (ABBV-621) is a recombinant fusion protein agonist of the TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) death receptors, designed to induce apoptosis in cancer cells expressing these receptors. *Bortezomib* is a small molecule proteasome inhibitor that disrupts proteasomal protein degradation, leading to apoptosis in multiple myeloma cells. *Dexamethasone* is a synthetic glucocorticoid corticosteroid that exerts broad anti-inflammatory and immunosuppressive effects and is used in multiple myeloma regimens to decrease tumor burden and reduce inflammation. The combination is given to adults with relapsed/refractory multiple myeloma, aiming to enhance anti-myeloma activity through complementary mechanisms including apoptosis induction, proteasome inhibition, and immunomodulation. This regimen is in clinical phase evaluation and not yet approved, with studies focusing on establishing the recommended phase 2 dose and assessing disease symptom changes[2][4][6][8].
- Other names
- eftozanermin alfa + bortezomib + dexamethasone
02
Targets
GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)TNFRSF10A (Death receptor 4)TNFRSF10B (DR5)
Beyond the preview
Go deeper on eftozanermin alfa + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eftozanermin alfa + bortezomib + dexamethasone.